Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.
Discover the most-read SMA stories of 2025, featuring updates on the gene therapy Zolgensma, next-generation treatments, and ...
Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over 2 years old.
CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein ...
The Biogen/Dayra partnership is driven by the strategic potential of oral macrocyclic peptides. This emerging therapeutic approach aims to deliver biologic-like efficacy and safety in a convenient ...
– New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the ...
Good morning, everyone. Welcome to day 2 at the 37th Annual Piper Sandler Healthcare Conference. This is David Amsellem from the Piper biopharma research team. We're delighted to have Biogen with us.
November 24, 2025, 2:02 PM ESTHealth Care November 19, 2025, 9:57 AM ESTHealth Care November 13, 2025, 4:05 PM ESTHealth Care November 19, 2025, 11:27 AM ESTCommercial Real Estate November 05, 2025, 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback